Multivariate analyses of FcγRIIIa polymorphisms adjusting for IPI risk factors in patients treated with R-CHOP
| Variable . | Exp (coefficient) . | Lower 95% CI . | Upper 95% CI . | P . |
|---|---|---|---|---|
| EFS | ||||
| FF vs VF/VV | 1.55 | 0.898 | 2.68 | .120 |
| LDH | 1.84 | 1.126 | 3.02 | .015 |
| ECOG > 1 | 1.35 | 0.759 | 2.41 | .310 |
| Stage 3/4 | 1.58 | 0.904 | 2.77 | .110 |
| Extranodal sites ≥ 2 | 1.47 | 0.847 | 2.56 | .170 |
| PFS | ||||
| FF vs VF/VV | 1.80 | 0.996 | 3.25 | .052 |
| LDH | 2.18 | 1.257 | 3.78 | .006 |
| ECOG > 1 | 1.45 | 0.777 | 2.71 | .240 |
| Stage 3/4 | 1.59 | 0.847 | 2.98 | .150 |
| Extranodal sites ≥ 2 | 1.68 | 0.921 | 3.05 | .091 |
| OS | ||||
| FF vs VF/VV | 1.35 | 0.708 | 2.56 | .360 |
| LDH | 2.30 | 1.294 | 4.09 | .005 |
| ECOG | 1.44 | 0.761 | 2.73 | .260 |
| Stage 3/4 | 1.40 | 0.742 | 2.66 | .300 |
| Extranodal sites ≥ 2 | 1.44 | 0.770 | 2.69 | .250 |
| Variable . | Exp (coefficient) . | Lower 95% CI . | Upper 95% CI . | P . |
|---|---|---|---|---|
| EFS | ||||
| FF vs VF/VV | 1.55 | 0.898 | 2.68 | .120 |
| LDH | 1.84 | 1.126 | 3.02 | .015 |
| ECOG > 1 | 1.35 | 0.759 | 2.41 | .310 |
| Stage 3/4 | 1.58 | 0.904 | 2.77 | .110 |
| Extranodal sites ≥ 2 | 1.47 | 0.847 | 2.56 | .170 |
| PFS | ||||
| FF vs VF/VV | 1.80 | 0.996 | 3.25 | .052 |
| LDH | 2.18 | 1.257 | 3.78 | .006 |
| ECOG > 1 | 1.45 | 0.777 | 2.71 | .240 |
| Stage 3/4 | 1.59 | 0.847 | 2.98 | .150 |
| Extranodal sites ≥ 2 | 1.68 | 0.921 | 3.05 | .091 |
| OS | ||||
| FF vs VF/VV | 1.35 | 0.708 | 2.56 | .360 |
| LDH | 2.30 | 1.294 | 4.09 | .005 |
| ECOG | 1.44 | 0.761 | 2.73 | .260 |
| Stage 3/4 | 1.40 | 0.742 | 2.66 | .300 |
| Extranodal sites ≥ 2 | 1.44 | 0.770 | 2.69 | .250 |